Antiglioma effects of a new, low molecular mass, inhibitor of fibroblast growth factor

Neuroscience Letters

Volumn 491, Issue 1, 2011, Pages 1-7

  Cuevas, Pedro ^a   Carceller, Fernando ^b   Angulo, Javier ^a   González Corrochano, Rocío ^a   Cuevas Bourdier, Adrián ^c   Giménez Gallego, Guillermo ^d  

^a INSTITUTO RAMÓN Y CAJAL DE INVESTIGACIÓN SANITARIA IRYCIS   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c Servicio de Anatomía Patológica Hospital   (Spain)

^d CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

Author keywords

2,5 Dihydroxyphenylsulfonate (2,5DHPS); Chemoresistance; Dobesilate; FGF; Glioblastoma

Indexed keywords

2,5 DIHYDROXYBENZENESULFONIC ACID; ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR INHIBITOR; IRINOTECAN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER INVASION; CONTROLLED STUDY; GLIOBLASTOMA; GLIOMA CELL; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CALCIUM DOBESILATE; CELL LINE, TUMOR; FIBROBLAST GROWTH FACTORS; GLIOMA; NEOPLASMS, EXPERIMENTAL; RATS;

EID: 79951515139     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2010.12.047     Document Type: Article

References (18)

1. Casanovas O., Hicklin D.J., Bergers G., Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signalling in late-stage pancreatic islet tumors. Cancer Cell 2005, 8:299-309.
2. Cohen B.A., Knopp E.A., Rusinek H., Babb J.S., Zagzag D., Gomen O. Assessing global invasion of newly diagnosed glial tumors with whole-brain proton MR spectroscopy. Am. J. Neuroradiol. 2005, 26:2170-2177.
3. Cuevas P., Carceller F., Diaz D., Reimers D., Fernández M., Lozano R.M., González-Corrochano R., Giménez-Gallego G. Abolished angiogenicity and tumorigenicity of rat glioma by 1-naphthalenemonosulfate. Neurosci. Lett. 2001, 30:185-188.
4. Cuevas P., Diaz-González D., Dujovny M. Dihidroxy-2,5-benzene-sulfonate (dobesilate) elicits growth arrest and apoptosis in glioma cells. Neurol. Res. 2005, 27:797-800.
5. DeAngelis L.M. Brain tumors. N. Engl. J. Med. 2001, 344:114-123.
6. Engenbroaten O., Bjerkvig R., Pedersen P.H., Laerun O.D. Effects of EGF, bFGF, NGF and PDGF (bb) on cell proliferative, migratory and invasive capacities of human brain-tumors biopsies in vitro. Int. J. Cancer 1993, 53:209-214.
7. Fernández I.S., Cuevas P., Angulo J., López-Navajas P., Canales-Mayordomo A., Lozano R.M., Valverde S., Jiménez-Barbero J., Romero A., Giménez-Gallego G. Gentisic acid, a compound associated with plant defense and a metabolite of aspirin, heads a new class of in vivo FGF inhibitor. J. Biol. Chem. 2010, 285:11714-11729.
8. Haritoglou C., Gerss J., Sauerland C., Kampik A., Ulbig M.W. CALDIRET study group, effect of calcium dobesilate on occurrence of diabetic macular oedema (CALDIRECT study): randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2009, 373:1316-1318.
9. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., Griffing S., Holmgren E., Ferrara N., Fyfe G., Rogers B., Ross R., Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004, 350:2335-2342.
10. Jonca F., Ortega N., Gleizes P.E., Bertrand N., Plouet J. Cell release of bioactive fibroblast growth factor 2 by exon 6-encoded sequence of vascular endothelial growth factor. J. Biol. Chem. 1997, 272:24203-24209.
11. Lund-Johansen M., Forsberg K., Bjerkvig R., Laerum O.D. Effects of growth factors on a human glioma cell line during invasion into rat brain aggregates in culture. Acta Neuropathol. 1992, 84:190-197.
12. Norden A.D., Drappatz J., Wen P.Y. Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol. 2008, 7:1152-1160.
13. Okumura N., Takimoto K., Okada M., Nakagawa H.J. C6 glioma cells produce basic fibroblast growth factor that can stimulate their own proliferation. Biochemistry 1989, 106:904-909.
14. Paez-Ribes M., Allen E., Hudock J., Takeda T., Okuyama H., Vinals F., Inoue M., Bergers G., Hanahan D., Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15:220-231.
15. Song S., Wientjes M.G., Gan Y., Au J.L.S. Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:8658-8663.
16. Surawicz T.S., McCarthy B.J., Kupelian V., Jukich P.J., Brunner J.M., Davis F.G. Descriptive epidemiology of primary brain and CNS tumors: results from the Central Brain Tumor Register in the United States, 1990-1994. Neuro Oncol. 1999, 1:14-25.
17. Xu T., Chen J., Lu Y., Wolff J.E.A. Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systemic review and survival-gain analyses. BMC Cancer 2010, 10:252. 10.1186/1471-2407.
18. Zhang Y., Song S., Yang F., Au J.L.S., Wientjes M.G. Nontoxic doses of suramin enhance activity of Doxorubicin in prostate tumors. J. Pharmacol. Exp. Ther. 2001, 299:426-433.